Results 11 to 20 of about 15,231 (118)

Inhibition of colorectal cancer targets IL-6, CTLA-4, & B7-2 by Tislelizumab: molecular docking, dynamics, & STRING protein-protein network analysis

open access: yesInformatics in Medicine Unlocked, 2023
As a DNA mismatch repair deficit (dMMR) anticancer medication, and a humanized monoclonal antibody (hmAb), Tislelizumab has attracted significant interest in recent years.
Mahmoud Elkazzaz   +11 more
doaj   +1 more source

Expression of programmed cell death ligand-1 and mismatch repair status in endometrial carcinomas

open access: yesJournal of Mid-Life Health, 2023
Background and Aims: Programmed death ligand-1 (PD-L1) is a co-regulatory molecule that suppresses local immunity, and mismatch repair (MMR) deficiency (dMMR) is reported to influence the response to anti-PD-L1-targeted therapy.
Madhubala Rajendran   +7 more
doaj   +1 more source

Hepatitis B core antigen upregulates B7-H1 on dendritic cells by activating the AKT/ERK/P38 pathway: a possible mechanism of hepatitis B virus persistence [PDF]

open access: yesLaboratory Investigation, 2016
B7-H1 binding to programmed death-1 may deliver a coinhibitory signal to T cells that is involved in the regulation of T-cell activation and tolerance. B7-H1 plays a key role in dysfunction of dendritic cells (DCs) during chronic HBV infection, but the expression mechanism of B7-H1 remains unclear.
Man, Li   +8 more
openaire   +2 more sources

Immunoexpression of PD-L1, CD4+ and CD8+ cell infiltrates and tumor-infiltrating lymphocytes (TILs) in the microenvironment of actinic cheilitis and lower lip squamous cell carcinoma

open access: yesJournal of Applied Oral Science, 2022
Lower lip squamous cell carcinomas (LLSCC) could be associated with a previous history of potentially malignant oral diseases (PMOD), especially actinic cheilitis (AC), with high sun exposure being a well-described risk factor. Immune evasion mechanisms,
Vinícius Gonçalves de Souza   +7 more
doaj   +1 more source

B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models

open access: yesOncoImmunology, 2020
The application of chimeric antigen receptor (CAR)-T cell therapy in patients with advanced solid tumors remains a significant challenge. Simultaneously targeting antigen and the solid tumor microenvironment are two major factors that greatly impact CAR ...
Baozhu Huang   +8 more
doaj   +1 more source

Targeting the PD-1/PD-L1 Axis in Human Vitiligo

open access: yesFrontiers in Immunology, 2020
Autoreactive CD8+ T cells play a pivotal role in melanocyte destruction in autoimmune vitiligo. Immunotherapy for melanoma often leads to autoimmune side-effects, among which vitiligo-like depigmentation, indicating that targeting immune checkpoints can ...
Marcella Willemsen   +3 more
doaj   +1 more source

Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells

open access: yesHaematologica, 2013
Clinical trials of immunotherapy in mantle cell lymphoma have not yet delivered desirable results, partly because of the inhibitory machinery of the tumor and its microenvironment.
Lijuan Wang   +14 more
doaj   +1 more source

Immunohistochemical Expression of Programmed Death Ligand-1 in Tumour Milieu of Oral Cancer

open access: yesAnnals of Abbasi Shaheed Hospital and Karachi Medical & Dental College, 2020
Objectives: To determine the immunohistochemical expression of PD-L1 in oral squamous cell carcinoma and to correlate it with clinicopathological parameters.
Moomal Aslam Khan   +3 more
doaj   +1 more source

Silencing B7-H1 enhances the anti-tumor effect of bladder cancer antigen-loaded dendritic cell vaccine in vitro

open access: yesOncoTargets and Therapy, 2014
The aim of this study was to examine whether short hairpin RNA (shRNA) expressing lentiviral particles targeting B7-H1 infection could result in B7-H1 knockdown on dendritic cells (DCs) and to investigate whether B7-H1 silencing could augment the immune function of DCs and further elicit a more potent anti-tumor immune effect against bladder cancer ...
Wang,Shuo   +7 more
openaire   +4 more sources

PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo

open access: yesBiomarker Research, 2020
Background On-target off-tumor toxicity impedes the clinical application of chimeric antigen receptor-modified T cells (CAR-T cells) in the treatment of solid tumors.
Qibin Liao   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy